Journal Watch · British Journal of Pharmacology · 2026

Decoding fatal toxic effects in checkpoint inhibitor therapy using real-world pharmacovigilance data and machine learning.

The SAFE-ICI model demonstrated robust performance in predicting fatal irAE risk, successfully stratifying patients into low- and high-risk phenotypes with significantly different survival benefits, in both the discovery and holdout validation cohorts.<h4>Conclusion and implications</h4>Our findings highlight the potential of machine learning to improve pharmacovigilance systems and aid clinicians in enhancing patient outcomes during ICI therapy.

Yan D, Lyu B, Yu J et al.British Journal of Pharmacology3 min readPharma relevance 98/100

DOI: 10.1111/bph.70195PMID: 40948045Study type: cohort / observational clinical study

TL;DR

The SAFE-ICI model demonstrated robust performance in predicting fatal irAE risk, successfully stratifying patients into low- and high-risk phenotypes with significantly different survival benefits, in both the discovery and holdout validation cohorts.<h4>Conclusion and implications</h4>Our findings highlight the potential of machine learning to improve pharmacovigilance systems and aid clinicians in enhancing patient outcomes during ICI therapy.

Key findings

  • Combination therapies were associated with 20 fatal irAEs, including 3 in NSCLC, 6 in melanoma, 7 in RCC and 4 in other cancers, with stable involvement of multiple AE signals.
  • The SAFE-ICI model demonstrated robust performance in predicting fatal irAE risk, successfully stratifying patients into low- and high-risk phenotypes with significantly different survival benefits, in both the discovery and holdout validation cohorts.<h4>Conclusion and implications</h4>Our findings highlight the potential of machine learning to improve pharmacovigilance systems and aid clinicians in enhancing patient outcomes during ICI therapy.

What they did

A machine learning framework, SAFE-ICI, was developed to predict short-term risk and outcomes of fatal irAEs occurring within the first 90 days of ICI therapy.<h4>Key results</h4>The analysis identified 358 significant AE signals associated with ICI therapies across 18 organ systems. PD-1/PD-L1 therapies were associated with 54 fatal irAEs, including 23 in non-small cell lung cancer (NSCLC), 5 in melanoma, 6 in renal cell carcinoma (RCC) and 20 in other cancers.

Full abstract (original)

Background: <h4>Background and purpose</h4>Immune checkpoint inhibitors (ICIs) improve cancer outcomes but are also associated with immune-related adverse events (irAEs), which pose significant challenges for clinical management.<h4>Experimental approach</h4>An observational pharmacovigilance analysis on FDA Adverse Event Reporting System was performed to identify ICI-related adverse event (AE) signals. Fatality kinetics simulation and multivariate logistic regression were used to investigate patterns of fatal AEs and multisignal involvement.

What they did: A machine learning framework, SAFE-ICI, was developed to predict short-term risk and outcomes of fatal irAEs occurring within the first 90 days of ICI therapy.<h4>Key results</h4>The analysis identified 358 significant AE signals associated with ICI therapies across 18 organ systems. PD-1/PD-L1 therapies were associated with 54 fatal irAEs, including 23 in non-small cell lung cancer (NSCLC), 5 in melanoma, 6 in renal cell carcinoma (RCC) and 20 in other cancers.

Results & conclusions: Combination therapies were associated with 20 fatal irAEs, including 3 in NSCLC, 6 in melanoma, 7 in RCC and 4 in other cancers, with stable involvement of multiple AE signals. The SAFE-ICI model demonstrated robust performance in predicting fatal irAE risk, successfully stratifying patients into low- and high-risk phenotypes with significantly different survival benefits, in both the discovery and holdout validation cohorts.<h4>Conclusion and implications</h4>Our findings highlight the potential of machine learning to improve pharmacovigilance systems and aid clinicians in enhancing patient outcomes during ICI therapy.

Abstract © the authors / British Journal of Pharmacology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1111/bph.70195 · PubMed 40948045.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery, AI in drug discovery / diagnostics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery · AI in drug discovery / diagnostics

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this British Journal of Pharmacology study find?

The SAFE-ICI model demonstrated robust performance in predicting fatal irAE risk, successfully stratifying patients into low- and high-risk phenotypes with significantly different survival benefits, in both the discovery and holdout validation cohorts.<h4>Conclusion and implications</h4>Our findings highlight the potential of machine learning to improve pharmacovigilance systems and aid clinicians in enhancing patient outcomes during ICI therapy.

What type of study is this?

It is a cohort / observational clinical study, published in British Journal of Pharmacology in 2026. A machine learning framework, SAFE-ICI, was developed to predict short-term risk and outcomes of fatal irAEs occurring within the first 90 days of ICI therapy.<h4>Key results</h4>The analysis identified 358 significant AE signals associated with ICI therapies across 18 organ systems.

Where can I read the original paper?

The original is at the publisher via DOI 10.1111/bph.70195. PubMed ID: 40948045. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Yan D, Lyu B, Yu J et al.. Decoding fatal toxic effects in checkpoint inhibitor therapy using real-world pharmacovigilance data and machine learning.. British Journal of Pharmacology (2026). DOI: 10.1111/bph.70195.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/decoding-fatal-toxic-effects-in-checkpoint-inhibitor-therapy-using-real-h70195/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides